Maker of latest experimental vaccine not expected to seek authorization until June at the earliest

A 34-year-old Maryland biotechnology company that has never successfully launched a vaccine faces a world impatient for more coronavirus shots to quell a pandemic – but the wait isn’t over. Novavax, bolstered by $1.6 billion in federal funding, is unlikely to seek emergency use authorization for its coronavirus vaccine in the United States until June…

Read more

This website is using cookies to improve the user-friendliness. You agree by using the website further. Privacy policy

Skip to content